Zetol Antiseptic Recall Pakistan Public Alert 021/2026
Summary
NAFDAC issued Public Alert No. 021/2026 on March 25, 2026, advising the public of a recall of Zetol Antiseptic (batch BOOO1, Chloroxylenol, 100ml and 1L) manufactured by UNCUS BROTHERS, 23 KM Multan Road, Lahore, Pakistan. The Drug Regulatory Authority of Pakistan (DRAP) found the product is being sold without prior evaluation, registration, or approval and that its packaging closely resembles registered brand Dettol, potentially misleading consumers. NAFDAC instructed all zonal directors and state coordinators to conduct surveillance and remove any unregistered or counterfeit products found in their jurisdictions.
“Use of the unregistered antiseptic product "Zetol (Chloroxylenol) Germ Protection Liquid" may pose a potential risk to public health, as it has not been evaluated or approved, and so its quality, safety, and efficacy cannot be guaranteed.”
About this source
GovPing monitors NAFDAC Nigeria News & Alerts for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 3 changes logged to date.
What changed
NAFDAC issued a public alert regarding the recall of Zetol Antiseptic (batch BOOO1, 100ml and 1L, Chloroxylenol) manufactured by UNCUS BROTHERS in Lahore, Pakistan, after DRAP determined the product is marketed and sold without regulatory authorization. The product closely resembles Dettol packaging, raising consumer confusion risks. Use of unregistered Zetol may pose a potential risk to public health as its quality, safety, and efficacy cannot be guaranteed.
Importers, distributors, retailers, healthcare professionals, caregivers, and consumers are advised to exercise caution and vigilance within the supply chain to avoid importation, distribution, sale, or use of the product. All NAFDAC zonal directors and state coordinators have been instructed to conduct surveillance and remove any unregistered or counterfeit products in their jurisdictions. Healthcare professionals and consumers should report suspicions of substandard or falsified products to NAFDAC.
What to do next
- All NAFDAC zonal directors and state coordinators have been instructed to conduct surveillance and remove any unregistered or counterfeit products that may be present in their respective zones and states
- Healthcare professionals and consumers are advised to report any suspicion of the sale of substandard and falsified medicines, medical devices, or any NAFDAC-regulated product to the nearest NAFDAC office, call NAFDAC on 0800-162-3322, or via email: sf.alert@nafdac.gov.ng
- Healthcare professionals and patients are also encouraged to report adverse events or side effects related to the use of medicinal products or devices to the nearest NAFDAC office, or through the use of the E-reporting platforms available on the NAFDAC website www.nafdac.gov.ng, or via the Med-safety application available for download on Android and IOS stores, or via e-mail on pharmacovigilance@nafdac.gov.ng
Archived snapshot
Apr 25, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Also In Recalls and Safety Alerts
- Public Alert No. 023/2026 – Alert on Counterfeit Brands of Proguanil (Projeanil and Re-granil) Tablet B.P 100mg with Fake NAFDAC Registration Number (04-6433) found in Nigeria
- Public Alert No. 022/2026 – Alert on the Distribution of Unregistered and Suspected Counterfeit Colgate Toothpaste
- Public Alert No. 021/2026 -Alert on the Recall of Zetol Antiseptic Product in Pakistan
- Public Alert No. 020/2026 -Alert on Unregistered ViroActive+ Drug Purported to Cure HIV
Public Alert No.019/2026 – Alert on Mop up of all Otrivin Nasal Drops (0.05% and 0.1%)
March 25, 2026
The National Agency for Food and Drug Administration and Control (NAFDAC) is notifying the public about the recall of certain batches of Zetol Antiseptic Products in Islamabad, Pakistan, due to a quality defect.
The Drug Regulatory Authority of Pakistan (DRAP) has stated that this product is being marketed and sold in Pakistan without prior evaluation, registration, or approval from the Drug Regulatory Authority of Pakistan (DRAP).
Zetol contains an active antiseptic ingredient (Chloroxylenol) and is being promoted with claims of infection prevention, despite lacking regulatory authorization. Additionally, its packaging closely resembles that of a registered antiseptic brand, Dettol, which may mislead consumers and increase the risk of inappropriate use of this unregulated product.
Risk Statement
Use of the unregistered antiseptic product “Zetol (Chloroxylenol) Germ Protection Liquid” may pose a potential risk to public health, as it has not been evaluated or approved, and so its quality, safety, and efficacy cannot be guaranteed.
Product Details
The details of the product are as follows:
| No. | Product Name | Pack size | Composition | Batch Details | Manufacturer Name |
| 1 | Zetol Antiseptic | 100ml, 1 Litre | Chloroxylenol | BOOO1 | UNCUS BROTHERS Address: 23 KM Multan Road, Lahore |
Product Photo
NAFDAC wants to stress that unregistered products sold through unauthorized distribution channels are unsafe, and their effectiveness and quality are not guaranteed.
All NAFDAC zonal directors and state coordinators have been instructed to conduct surveillance and remove any unregistered or counterfeit products that may be present in their respective zones and states.
Importers, distributors, retailers, healthcare professionals, caregivers, and consumers are hereby advised to exercise caution and vigilance within the supply chain to avoid the importation, distribution, sale, and use of the SF product. All medical products must be obtained from authorized/licensed suppliers. The products’ authenticity and physical condition should be carefully checked.
Healthcare professionals and consumers are advised to report any suspicion of the sale of substandard and falsified medicines, medical devices, or any NAFDAC-regulated product to the nearest NAFDAC office, call NAFDAC on 0800-162-3322, or via email: sf.alert@nafdac.gov.ng
Similarly, healthcare professionals and patients are also encouraged to report adverse events or side effects related to the use of medicinal products or devices to the nearest NAFDAC office, or through the use of the E-reporting platforms available on the NAFDAC website www.nafdac.gov.ng, or via the Med- safety application available for download on Android and IOS stores, or via e-mail on pharmacovigilance@nafdac.gov.ng
For complaints, you can call the Reforms Unit on the following lines: 09097630506, 09097630507, or email: reforms@nafdac.gov.ng
Furthermore, note that this notice will be uploaded to the WHO Global Surveillance and Monitoring System (GSMS).
NAFDAC ………….Customer-focused, Agency-minded!!!
- Content Current as of April 2, 2026 More Actions
Parties
Related changes
Get daily alerts for NAFDAC Nigeria News & Alerts
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NAFDAC.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when NAFDAC Nigeria News & Alerts publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.